IL6 and Miyoshi myopathy: Consistent with published data that increased IL-6 signaling is a mechanism of doxorubicin resistance in MM, HDAC3-silencing in HS-5 cells attenuates cell adhesion mediated drug resistance (CAM-DR) against doxorubicin, but not bortezomib or lenalidomide (Fig. S17a, S17b) [12].